000128256 001__ 128256
000128256 005__ 20240228135048.0
000128256 0247_ $$2doi$$a10.1016/j.advms.2014.03.002
000128256 0247_ $$2pmid$$apmid:24797991
000128256 0247_ $$2ISSN$$a0067-6489
000128256 0247_ $$2ISSN$$a1427-941X
000128256 0247_ $$2ISSN$$a1896-1125
000128256 0247_ $$2ISSN$$a1896-1126
000128256 0247_ $$2ISSN$$a1898-4002
000128256 037__ $$aDKFZ-2017-04273
000128256 041__ $$aeng
000128256 082__ $$a610
000128256 1001_ $$aSchildberg, Claus Wilhelm$$b0
000128256 245__ $$aGastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations.
000128256 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2014
000128256 3367_ $$2DRIVER$$aarticle
000128256 3367_ $$2DataCite$$aOutput Types/Journal article
000128256 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523518364_23616
000128256 3367_ $$2BibTeX$$aARTICLE
000128256 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128256 3367_ $$00$$2EndNote$$aJournal Article
000128256 520__ $$aThere is an increasing need to identify molecular markers, which can be used to prognosticate patient populations in gastric cancer. Whereas a significant number have been identified, very few have been characterized in the context of their ability to discriminate between young and old age groups in which a survival difference clearly exists.In this study, using immunohistochemistry, we evaluated three markers with proven involvement in gastric cancer. The p53 tumor suppressor, the cell adhesion glycoprotein epithelial cadherin (CDH1) and the caudal-related homeobox transcription factor (CDX2) all of these have important roles in the aetiopathogenesis and/or progression of gastric cancer.After adjustments for TNM stage, tumor grade, histopathological characteristics (Lauren classification), we found significant differences in the expression of these proteins, particularly E-cadherin and CDX2 between young and elderly patients. However, these differences did not amount to a significant difference in survival.This study demonstrates that the protein expression of p53, CDH1 and CDX2 significantly discriminates young patients with gastric cancer who have a better prognostic outlook from older patients, but this difference in expression does not contribute to a survival benefit.
000128256 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000128256 588__ $$aDataset connected to CrossRef, PubMed,
000128256 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000128256 650_7 $$2NLM Chemicals$$aCDX2 Transcription Factor
000128256 650_7 $$2NLM Chemicals$$aCDX2 protein, human
000128256 650_7 $$2NLM Chemicals$$aCadherins
000128256 650_7 $$2NLM Chemicals$$aHomeodomain Proteins
000128256 7001_ $$0P:(DE-He78)54a8723466e5d487247f3d93d51c66bc$$aAbba, Mohammed Lawan$$b1$$udkfz
000128256 7001_ $$aMerkel, Susanne$$b2
000128256 7001_ $$aAgaimy, Abbas$$b3
000128256 7001_ $$aDimmler, Arno$$b4
000128256 7001_ $$aSchlabrakowski, Anne$$b5
000128256 7001_ $$aCroner, Roland$$b6
000128256 7001_ $$0P:(DE-HGF)0$$aLeupold, Jörg Hendrik$$b7
000128256 7001_ $$aHohenberger, Werner$$b8
000128256 7001_ $$0P:(DE-He78)69067807288b48415ceb4abc43b9ad54$$aAllgayer, Heike$$b9$$eLast author$$udkfz
000128256 773__ $$0PERI:(DE-600)2273671-2$$a10.1016/j.advms.2014.03.002$$gVol. 59, no. 1, p. 142 - 146$$n1$$p142 - 146$$tAdvances in medical sciences$$v59$$x1896-1126$$y2014
000128256 909CO $$ooai:inrepo02.dkfz.de:128256$$pVDB
000128256 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54a8723466e5d487247f3d93d51c66bc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128256 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000128256 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69067807288b48415ceb4abc43b9ad54$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128256 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000128256 9141_ $$y2014
000128256 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128256 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128256 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bADV MED SCI-POLAND : 2015
000128256 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128256 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128256 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128256 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128256 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128256 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128256 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128256 9201_ $$0I:(DE-He78)G360-20160331$$kG360$$lKKE Molekulare Onkologie solider Tumoren$$x0
000128256 980__ $$ajournal
000128256 980__ $$aVDB
000128256 980__ $$aI:(DE-He78)G360-20160331
000128256 980__ $$aUNRESTRICTED